Half-year report · Q2
2934.TEDINET S100V313
Period2024-06-01 → 2024-11-30
Filed2025-01-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Amended by S100V3GI (2025-01-15). Amended by S100VCMY (2025-03-06).
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.8bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Revenue | ¥17.7bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥8.0bn | 2023-06-01 → 2023-11-30 | Cons. | Net sales |
| Operating income | ¥131m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Operating income | −¥221m | 2023-06-01 → 2023-11-30 | Cons. | Operating income |
| Ordinary income | ¥112m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Ordinary income | −¥643m | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥232m | 2023-06-01 → 2023-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥118m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Profit before tax | −¥233m | 2023-06-01 → 2023-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥8m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥2.1bn | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥287m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥53m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Net income | −¥284m | 2023-06-01 → 2023-11-30 | Cons. | Profit loss |
| Total assets | ¥9.1bn | at 2024-11-30 | Cons. | Assets |
| Total assets | ¥10.7bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥7.4bn | at 2023-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.5bn | at 2024-11-30 | Cons. | Liabilities |
| Total liabilities | ¥9.1bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.7bn | at 2024-11-30 | Cons. | Net assets |
| Net assets / equity | ¥1.6bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥3.1bn | at 2023-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.9bn | at 2024-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.8bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2023-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2023-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥13m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥971m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥220m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.8bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥300m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥139m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.4bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥933m | 2023-06-01 → 2023-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥1.58 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-426.06 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-59.33 | 2023-06-01 → 2023-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥1.56 | 2024-06-01 → 2024-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 12.7% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 10.8% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.1% | at 2023-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2024-11-30 | −¥109m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥180m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥4.7bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥4.6bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥96m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥24m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.2bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥11m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥100m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥3.1bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥2m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥236m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥10.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-06-01 → 2024-11-30 | ¥109m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥312m |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2023-11-30 | −¥115m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2023-11-30 | −¥290m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.4bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.3bn |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥114m |
| jpcrp040300-q2r_E33800-000Healthcare Marketing Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥19m |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥2.0bn |
| jpcrp040300-q2r_E33800-000Healthcare Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥6m |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue external | 2023-06-01 → 2023-11-30 | ¥3.7bn |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥958,000 |
| jpcrp040300-q2r_E33800-000Medical Care Sales Businessreportable segment | segment profit | 2023-06-01 → 2023-11-30 | ¥44m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-06-01 → 2023-11-30 | ¥8.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-06-01 → 2023-11-30 | ¥8.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-06-01 → 2023-11-30 | ¥115m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-06-01 → 2023-11-30 | ¥69m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 533
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 10843838000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 1900000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E33800-000HealthcareSalesBusinessReportableSegmentMember | 10600000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 96088000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 108589000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -108589000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 3076722000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E33800-000HealthcareSalesBusinessReportableSegmentMember | 3193347000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E33800-000HealthcareMarketingBusinessReportableSegmentMember | 4682357000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 10952428000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -108589000 | JPY |
| Net sales | CurrentYTDDuration | 10843838000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E33800-000MedicalCareSalesBusinessReportableSegmentMember | 235555000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E33800-000HealthcareSalesBusinessReportableSegmentMember | 100404000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E33800-000HealthcareMarketingBusinessReportableSegmentMember | -24110000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 311850000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -180419000 | JPY |
| Operating income | CurrentYTDDuration | 131430000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-01-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第17期中(自 2024年６月１日 至 2024年11月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ジェイフロンティア株式会社 | |
| Company name in english cover page | FilingDateInstant | J Frontier Co.,Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長執行役員 中村 篤弘 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区桜丘町９番８号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03-6427-4662（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員経営企画本部長 樋口 雄也 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区桜丘町９番８号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03-6427-4662（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員経営企画本部長 樋口 雄也 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E33800 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 29340 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ジェイフロンティア株式会社 | |
| Filer name in english | FilingDateInstant | J Frontier Co.,Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-06-01 | |
| Current period end date | FilingDateInstant | 2024-11-30 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |